Benedict Financial Advisors Inc. Boosts Holdings in Amgen Inc. (AMGN)

Benedict Financial Advisors Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,723 shares of the medical research company’s stock after acquiring an additional 377 shares during the period. Amgen comprises approximately 2.1% of Benedict Financial Advisors Inc.’s portfolio, making the stock its 14th largest position. Benedict Financial Advisors Inc.’s holdings in Amgen were worth $4,095,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of AMGN. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Amgen in the first quarter worth $110,402,000. Swiss National Bank grew its stake in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after acquiring an additional 551,600 shares in the last quarter. Bank of Nova Scotia grew its stake in shares of Amgen by 414.4% in the first quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after acquiring an additional 484,868 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Amgen by 37.4% in the first quarter. AQR Capital Management LLC now owns 1,443,129 shares of the medical research company’s stock worth $236,775,000 after acquiring an additional 392,538 shares in the last quarter. Finally, Morningstar Investment Services LLC grew its stake in shares of Amgen by 283.8% in the first quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after acquiring an additional 367,894 shares in the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.

Shares of Amgen Inc. (AMGN) opened at 185.79 on Wednesday. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The stock has a 50 day moving average of $182.35 and a 200-day moving average of $170.56. The stock has a market capitalization of $135.57 billion, a PE ratio of 16.92 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same period last year, the firm posted $2.84 EPS. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.

In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.19% of the company’s stock.

Several research firms have commented on AMGN. UBS AG restated a “neutral” rating and issued a $175.00 price target (up previously from $174.00) on shares of Amgen in a research note on Tuesday, June 13th. Morgan Stanley boosted their price target on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price target for the company. in a research note on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Royal Bank Of Canada initiated coverage on shares of Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price objective for the company. Ten investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $189.99.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/10/11/benedict-financial-advisors-inc-boosts-holdings-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply